Where the fluid comes from: this is a gland question, not a sperm question
Most of what leaves the body at ejaculation was never sperm to begin with.
Sperm cells, made in the testes, make up under 10% of the fluid by volume. The rest is seminal plasma, and that plasma comes overwhelmingly from two glands: the seminal vesicles and the prostate.
| Source | Share of ejaculate volume | What it adds |
|---|---|---|
| Seminal vesicles | About two-thirds | Fructose-rich fluid that fuels sperm and makes up the bulk of the total |
| Prostate | About one-third | Enzymes and zinc-rich fluid that liquefies the sample after ejaculation |
| Testes and epididymis | Up to 10% | Sperm cells themselves, plus epididymal fluid |
| Bulbourethral glands | A small component (no figure given) | A small pre-ejaculate contribution |
The two glands that decide most of the total are not where sperm is made, so a lever that only raises sperm count would not be expected to move the number much; a trial reporting "improved sperm parameters" is very often about count and motility, not volume.
Sources for the gland shares and the under-10% sperm figure
Gland contribution shares per Roberts and Jarvi, "Steps in the investigation and management of low semen volume in the infertile man," Can Urol Assoc J 2009, PMID 20019978. Sperm-share figure per Healthline's review of this product category, read in recon, 2026-08-28.
The abstinence interval is the biggest single lever you actually control
The World Health Organization's laboratory manual asks for 2 to 7 days of ejaculatory abstinence before a semen sample is collected, because volume and sperm count are abstinence-dependent: a sample after one day is systematically different from one after five. Within that window volume tends to climb across the first several days, with the gain per extra day shrinking and the exact plateau varying by study; more recent IVF-focused research favors shorter intervals for sperm DNA integrity, so "more abstinence" does not help every measure at once. Compare your own samples only at the same interval and the same time of day.
Why a two-day and a six-day sample are not comparable, and the WHO and review sources
Testing once after two days and once after six, then reading the difference as a result, measures the abstinence window, not anything else.
Abstinence-window guidance per the WHO's laboratory manual for the examination and processing of human semen (5th edition, 2010, and 6th edition, 2021). Abstinence-effect literature summarized from published systematic reviews of the ejaculatory-abstinence interval, including a 2021 review in the assisted-reproduction literature and a 2022 report favoring shorter intervals for DNA fragmentation specifically; findings vary by outcome and are not a single named trial.
Hydration is a ceiling, not a lever
Seminal plasma is mostly water, so dehydration, which lowers bodily secretions generally, could lower ejaculate volume too; nothing in our research turned up a trial showing that extra water on top of normal hydration adds volume. The one measurement worth taking is urine color, not ounces: light straw to pale yellow is the standard clinical marker of adequate hydration, darker urine suggests topping up, and colorless urine for long stretches can mean over-hydration.
The urine-color criterion and its source, and what no trial has tested
The one measurement worth taking: urine color, not ounces. Light straw to pale yellow is the standard clinical marker of adequate hydration; darker urine suggests topping up, and colorless urine for long stretches can mean over-hydration.
Urine-color criterion per published hydration-assessment research using the CIE L*a*b* color scaleThat is a genuinely useful substitute for the vague advice to "drink more water": check the color, aim for pale straw, and treat that as the finished task rather than a number of glasses to hit.
Hydration-and-secretion relationship is general physiology; no trial testing hydration or fluid intake against ejaculate volume as an endpoint was found in this research. Ingredient trials that did measure volume as an endpoint are in the table below. Urine-color criterion per hydration-assessment literature using objective colorimetry, published 2020.
Medications and conditions that lower volume, and when that is a doctor's question
Some of the biggest drops in ejaculate volume are drug-class effects or a disease process. 5-alpha-reductase inhibitors: a one-year trial in healthy men found semen volume down 29.7% on dutasteride 0.5 mg (statistically significant) and 14.5% on finasteride 5 mg (not significant); the 1 mg hair-loss dose did not significantly change semen production over 48 weeks. Alpha-blockers: tamsulosin 0.8 mg cut volume by a mean 2.4 mL in a 5-day crossover of 48 healthy men, with 35.4% producing no ejaculate at all, while alfuzosin and placebo rose. Longstanding diabetes: retrograde ejaculation in roughly a third of men with diabetes in one controlled study, none of the controls. See a urologist for a persistent reading under the WHO's 1.4 mL lower reference limit on more than one sample at a standard interval, or a sudden drop from your own normal, especially with a new medication, cloudy urine after sex, or any pain.
The three cards with trial details and PMIDs, the two urologist criteria spelled out, and the sources
Used for hair loss (1 mg) or an enlarged prostate (5 mg). A 48-week trial found the 1 mg dose did not significantly change semen production in young men; a separate one-year trial in healthy men (Amory et al., J Clin Endocrinol Metab 2007, PMID 17299062) found semen volume down 29.7% on dutasteride 0.5 mg (statistically significant) and 14.5% on finasteride 5 mg (not significant) at 52 weeks.
In a 5-day, randomized, three-way crossover in 48 healthy men, tamsulosin 0.8 mg (double the usual clinical dose) cut ejaculate volume by a mean 2.4 mL while alfuzosin and placebo rose 0.3 to 0.4 mL; 89.6% of men had a volume drop over 20% and 35.4% produced no ejaculate at all, an effect the authors did not attribute to retrograde ejaculation (Hellstrom and Sikka, J Urol 2006, PMID 16952675). The same crossover's sperm report found total sperm count fell 54.6 million on tamsulosin while rising on placebo and alfuzosin (J Androl 2009, PMID 19201696).
Chronic high blood sugar can damage the nerves that keep the bladder neck closed during ejaculation, sending semen backward into the bladder. One controlled study found this in roughly a third of men with diabetes, versus none of the matched controls.
Two criteria, either one is enough
- A persistent reading under the WHO's 1.4 mL lower reference limit, confirmed on more than one sample at a standard 2 to 7 day interval, not a single low reading after a short abstinence window.
- A sudden drop from your own normal, especially alongside a new medication, cloudy urine after sex (a sign worth mentioning, and one that can point toward retrograde flow), or any pain.
Finasteride figures per a chronic-treatment trial in young men (PMID 10492183) and a one-year trial in healthy men, Amory et al., J Clin Endocrinol Metab 2007, PMID 17299062, reporting semen volume down 29.7% on dutasteride 0.5 mg (statistically significant) and 14.5% on finasteride 5 mg (not significant) at 52 weeks. Alpha-blocker figures per Hellstrom and Sikka, J Urol 2006 (PMID 16952675) and J Androl 2009 (PMID 19201696). Diabetes prevalence per Fedder et al., Andrology, 2013;1(4):602 to 606. Lower reference limit per the WHO's 6th-edition laboratory manual, 2021.
Ingredients with actual trials, ranked by whether they even measured volume
Four ingredients show up constantly on volume-supplement labels. Here is what their own cited trials measured, and whether volume was an endpoint at all.
| Ingredient | Studied daily dose | What was measured | Result | Was volume an endpoint? |
|---|---|---|---|---|
| Zinc | 30 mg elemental zinc, plus 5 mg folic acid | Live birth plus six semen parameters reported individually (concentration, motility, morphology, volume, DNA fragmentation, total motile sperm count), n=2,370 men, 6 months (the FAZST trial) | No significant improvement over placebo; volume 3.5 mL in both arms, adjusted difference 0 (-0.2 to 0.2) | Yes, measured on its own: no gain |
| L-carnitine + L-acetylcarnitine | 2,000 mg + 1,000 mg a day (1,000 mg + 500 mg per dose, twice daily) | Volume, motility, vitality, DNA fragmentation, n=175 men, 6 months | Volume, motility and vitality improved significantly from baseline at 6 months (p<0.001); the abstract reports no medians | Yes, and positive, but inside a multi-ingredient product |
| L-arginine | 1,000 mg | Total sperm count, motility, and ejaculate volume, n=15 men, over a 2018 study window of about five months | All three reportedly increased versus baseline | Yes, but a small trial in a minor regional journal, not independently replicated |
| L-lysine | Commonly 250 mg on combination labels | No dedicated human trial on any semen parameter was found | Not established | No standalone trial found |
The largest, best-designed trial here (zinc, 2,370 men) measured volume directly and found a difference of exactly zero; every volume increase reported behind these rows rests on weaker evidence, and one common label ingredient has no dedicated trial at all.
The pattern row by row, the 2016 zinc meta-analysis pooled against baseline rather than placebo, and the sources for each row
Read row by row and a pattern appears: the largest, best-designed trial here (zinc, 2,370 men) measured volume directly and found a difference of exactly zero. Every volume increase reported anywhere behind these rows rests on weaker evidence than that: a multi-ingredient carnitine product, one small unreplicated 15-man study reported only against its own baseline, and six zinc studies in 563 infertile men that a 2016 meta-analysis pooled as before-and-after comparisons rather than against placebo, which the placebo-controlled 2,370-man trial outweighs. One common label ingredient has no dedicated trial at all.
None of that means these ingredients do nothing. It means the honest claim is narrower than "this ingredient increases ejaculate volume," and a label citing a study should be read for exactly which of these four boxes that study ticked.
Zinc trial: Schisterman et al., "Folic Acid and Zinc Supplementation Trial (FAZST)," JAMA, 2020, PMID 31910279. A 2016 meta-analysis, Zhao et al., Sci Rep 2016, PMID 26932683, pooled six earlier zinc studies in 563 infertile men as before-and-after comparisons rather than against placebo and did report a semen-volume increase (standardized mean difference -0.99, 95% CI -1.60 to -0.38); the placebo-controlled 2,370-man trial outweighs them. Carnitine combination trial: PMID 30873633. L-arginine trial: Manssor et al., Tikrit Journal of Pure Science, 2019;24(5), n=15; DOI 10.25130/tjps.v24i5.408, whose publisher domain no longer serves the article, so we read the paper's abstract through its Crossref record, Sep 7, 2026. L-lysine: no PubMed-indexed human trial located in this research as of the date filed.
A two-month self-test protocol, if you want an actual answer for your own body
Everything above is population-level evidence. The only way to know what moves your own number is a small, controlled personal test; two months roughly matches the turnover time physiologists give for a full cycle of sperm production and gland secretion.
The four steps: fix the interval, fix the time of day, change one variable at a time, and get a clinical semen analysis before and after
Fix the interval
Pick a number inside the WHO's 2 to 7 day window and keep it identical for every sample across the two months. Changing the interval between tests invalidates the comparison before anything else does.
Fix the time of day
Collect at the same time each round. Secretions can vary across the day, and this is a free source of noise a fixed schedule removes entirely.
Change one variable at a time
A hydration habit, one ingredient, one medication review with a doctor. Two variables changed together means neither one gets credit or blame for whatever the second test shows.
Get a real clinical semen analysis, before and after
This is the only objective measurement on this page. Labs typically measure volume gravimetrically, by weighing the collection container before and after, using a semen density close to 1 gram per mL, because pouring or pipetting a sample into a graduated cylinder is known to underestimate its true volume.
Two-month framing reflects general physiology for spermatogenesis and gland-secretion turnover, not a single named trial. Gravimetric measurement and the roughly 1 g per mL density figure per published semen-density and volume-measurement research, and per findings that decanting or pipetting underestimates ejaculate volume compared with weighing.
What the volume-supplement category claims, and what its one placebo-controlled trial measured
Behind at least one such product sits a real trial: a two-month, double-blind, placebo-controlled study of 63 men. Its honest headline is narrower than its ad copy. More men on the active product than on placebo showed a 20% or larger rise in ejaculate volume, a responder analysis, and global-assessment scores favored the product too. But the trial's primary endpoint, the average change in semen parameters across the group, did not reach statistical significance. The study also dosed twice the product's own daily label serving, so replicating the trial's protocol costs roughly double the sticker price.
The advertising register, and why a responder finding is a real signal but not a proven average effect
Search "how to increase ejaculate volume" and the advertising register shows up fast: dramatic before-and-after language, a "clinically proven" badge, and testimonials describing results the underlying study never claimed to produce.
A responder finding is a real signal, not the same as a proven average effect
- "Clinically proven" on an ad almost never specifies which endpoint proved it. A responder analysis (a threshold percentage of people who improved) and a primary-endpoint result (the average change across everyone) are two different claims, and only one of them is usually the one that failed.
- A trial's studied dose and a bottle's labeled daily serving are not guaranteed to match. When they do not, running the actual trial protocol can cost multiples of the advertised monthly price.
- None of this means the category is dishonest. It means the marketing register and the study's own fine print are two different documents, and only one of them is written to be read carefully.
Questions people also ask
How many days of abstinence give the highest ejaculate volume?
There is no single universal number. The WHO's laboratory manual asks for 2 to 7 days of abstinence before a semen analysis because volume is abstinence-dependent within that window, generally higher toward the far end, though exactly where it plateaus varies by study. What is fair is comparing a man's own samples only at the same interval and time of day; comparing a 2-day sample to a 6-day sample and calling the difference a result is not a real comparison.
Does drinking more water increase ejaculate volume?
Not beyond a normal hydration baseline. Seminal plasma is mostly water, and dehydration measurably lowers bodily secretions, but no trial in our research shows drinking beyond normal hydration adds volume on top of that baseline. The one measurement worth taking is urine color: light straw to pale yellow is the standard clinical marker of adequate hydration, a better check than counting extra glasses.
Which medications reduce ejaculate volume?
Two drug classes are the most studied. 5-alpha-reductase inhibitors (finasteride, dutasteride), used for hair loss or an enlarged prostate, are linked to reduced volume at the higher, prostate dose; one trial found the 1 mg hair-loss dose did not significantly change semen production over 48 weeks, while a one-year trial in healthy men (Amory et al., J Clin Endocrinol Metab 2007, PMID 17299062) found semen volume down 29.7% on dutasteride 0.5 mg (statistically significant) and 14.5% on finasteride 5 mg (not significant) at 52 weeks. Alpha-blockers (tamsulosin especially) can sharply reduce or eliminate ejaculate, an emission effect the trial authors did not attribute to retrograde ejaculation. Separately, longstanding diabetes can cause retrograde ejaculation, where semen enters the bladder instead of exiting, through nerve damage from chronic high blood sugar. See a urologist for a persistent reading under the WHO's 1.4 mL lower reference limit, or any sudden drop from your own normal.
Can a supplement increase ejaculate volume?
Few single-ingredient trials show a volume gain. The largest trial in this space (zinc, 2,370 men) measured volume directly and found none; the carnitine trial that did report a volume increase used a multi-ingredient product, so that result is not one ingredient's own proven effect; and the remaining positives are small, a 15-man L-arginine study reported only against its own baseline and six zinc studies in 563 infertile men that a 2016 meta-analysis pooled as before-and-after comparisons rather than against placebo, which the placebo-controlled 2,370-man trial outweighs. The volume-supplement category's own strongest evidence is typically one small, company-funded, placebo-controlled trial with a responder analysis, not a clear average-volume result across the whole group: a real signal worth reading closely, not the same thing as a proven increase.
How we built this page
This is a literature-and-label page, not a lab test, and not medical advice. Every number on it traces to a document we name, except where the src line says the point is a general literature finding.
The WHO manual editions, the urology review, the named trials and the recon behind each section
- Gland-contribution shares and the under-10%-sperm figure are drawn from a published urology review (PMID 20019978) and Healthline's review of this product category, read in recon dated 2026-08-28.
- The 2 to 7 day abstinence window is from the WHO's own laboratory manual (5th edition, 2010, and 6th edition, 2021); the 1.4 mL lower reference limit is from the 6th edition (2021), which replaced the 5th edition's 1.5 mL figure.
- The zinc, carnitine and L-arginine trial details are drawn from the named studies and their PubMed listings where one exists; the L-lysine line reflects that no such trial turned up in this research, not that none could ever exist.
- The medication and diabetes figures are drawn from the named clinical studies cited under that section.
- The 63-man trial described in the marketing section is drawn from a manufacturer's own published clinical-study summary and independent reads of it, recon dated 2026-08-28; we did not name the product in that section because the point is the pattern, not one brand.
- We did not test any product ourselves, and we did not estimate a number for anything we could not source.
Nothing here is medical advice; a persistent low reading, a new medication, or a fertility concern is a conversation with a doctor or urologist, not a page like this one.
The one product where we actually read the trial behind the marketing
If you decide to test a volume supplement anyway, our Semenax review reads the only placebo-controlled trial we found behind any volume-marketed supplement, its 20 percent responder finding and its double-dose fine print, matched against the label it is sold on, before you spend $59 on the first bottle.
Two tips: read the primary-endpoint line before the responder headline, and match the study's dose to the label's serving
Read the primary-endpoint line before the responder headline. Any ad that leads with "clinically proven" but never says whether the primary measure hit statistical significance is skipping the part that matters most.
Match the study's dose to the label's daily serving before buying multiple bottles. If a trial used double the label's amount, running the trial's actual protocol costs double the sticker price, not the advertised one.
The 63-man trial, the label's own doses, and the 20% responder threshold its ad is built on, each with the date we read it.